Anders Lonner - Karo Pharma Insider

KARBF -- USA Stock  

USD 4.00  0.45  12.68%

Chairman of the Board

Mr. Anders Lonner was Executive Chairman of the Board of Directors of Karo Pharma AB since February 4, 2015. He has previously been Independent Chairman of the Board since May 8, 2014. He holds MS in Political Science degree. He was previously Chief Executive Officer and President for Meda AB and had before then been CEO for Astra Lakemedel with responsibility for, among other things, Astras Nordic subsidiaries, CEO in Karo Bio AB and President of Lakemedelsforeningen. He is Advisor for EQT. In 2014 he was nominated Honorary Doctor of Medicine at Karolinska Institutet.
Age: 72  Chairman Since 2015      
46 1 03 30 23 10

Management Efficiency

The company has return on total asset (ROA) of 1.81 % which means that it generated profit of $1.81 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 1.26 % meaning that it generated $1.26 on every $100 dollars invested by stockholders.
The company has accumulated 293.75 M in total debt with debt to equity ratio (D/E) of 155.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karo Pharma AB has Current Ratio of 1.09 suggesting that it may not be capable to disburse its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Karo Pharma AB , a healthcare company, develops and markets products for elderly people in Sweden, Norway, Denmark, and Finland. Karo Pharma AB was founded in 1987 and is based in Stockholm, Sweden. Karo Pharma is traded on OTC Market in USA.Karo Pharma AB (KARBF) is traded on OTC Market in USA. It is located in Nybrokajen 7 and employs 39 people.

Karo Pharma AB Leadership Team

PerAnders Johansson, Director
Jean Lycke, Director
Per Johansson, Executive
Peter Blom, CEO
Henrik Palm, CFO
Anders Lonner, Chairman
Marianne Hamilton, Director
Maria Sjoberg, President
Hakan Astrom, Director
Thomas Kraft, Executive
Goran Wessman, Director
Bo Carlsson, Executive
Thomas Hedner, Director, MBA

Stock Performance Indicators

Current Sentiment - KARBF

Karo Pharma AB Investor Sentiment
Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Karo Pharma AB. What is your trading attitude regarding investing in Karo Pharma AB? Are you bullish or bearish?
50% Bullish
50% Bearish

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.